These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25255580)

  • 1. Risk factors and prescription patterns of gastroesophageal reflux disease: HEAL study in Pakistan.
    Butt AK; Hashemy I
    J Pak Med Assoc; 2014 Jul; 64(7):751-7. PubMed ID: 25255580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor utilization patterns in infants.
    Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic intent of proton pump inhibitor prescription among elderly nonsteroidal anti-inflammatory drug users.
    Dries AM; Richardson P; Cavazos J; Abraham NS
    Aliment Pharmacol Ther; 2009 Sep; 30(6):652-61. PubMed ID: 19573167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards.
    van Vliet EP; Steyerberg EW; Otten HJ; Rudolphus A; Knoester PD; Hoogsteden HC; van Gelder T; Kuijpers PM; Siersema PD
    Aliment Pharmacol Ther; 2009 Jan; 29(2):213-21. PubMed ID: 19006542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs.
    Thiéfin G; Schwalm MS
    Dig Liver Dis; 2011 Mar; 43(3):209-14. PubMed ID: 21051300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Suggested conduct by the Argentine Circle of Digestive Motility for the management of gastroesophageal reflux disease].
    Salis G; Soifer L; Solé L;
    Acta Gastroenterol Latinoam; 2013 Dec; 43(4):335-8. PubMed ID: 24516962
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors associated with gastroesophageal reflux disease relapse in primary care patients successfully treated with a proton pump inhibitor.
    López-Colombo A; Pacio-Quiterio MS; Jesús-Mejenes LY; Rodríguez-Aguilar JE; López-Guevara M; Montiel-Jarquín AJ; López-Alvarenga JC; Morales-Hernández ER; Ortiz-Juárez VR; Ávila-Jiménez L
    Rev Gastroenterol Mex; 2017; 82(2):106-114. PubMed ID: 28283313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of use of proton pump inhibitors in Greece.
    Ntaios G; Chatzinikolaou A; Kaiafa G; Savopoulos C; Hatzitolios A; Karamitsos D
    Eur J Intern Med; 2009 Mar; 20(2):171-3. PubMed ID: 19327607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-Impedance Findings and proton pump inhibitors-responsiveness in patients with typical gastroesophageal reflux disease symptoms in a large single-center Italian series.
    Vailati C; Mazzoleni G; Testoni PA; Passaretti S
    J Clin Gastroenterol; 2014 Aug; 48(7):613-9. PubMed ID: 24326754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors: a better prescription is needed.
    Khara HS; Pitchumoni CS
    J Clin Gastroenterol; 2009 Jul; 43(6):597-8. PubMed ID: 19384247
    [No Abstract]   [Full Text] [Related]  

  • 12. Do pediatricians apply the 2009 NASPGHAN-ESPGHAN guidelines for the diagnosis and management of gastroesophageal reflux after being trained?
    Quitadamo P; Urbonas V; Papadopoulou A; Roman E; Pavkov DJ; Orel R; Dias JA; Kostovski A; Miele E; Villani A; Staiano A
    J Pediatr Gastroenterol Nutr; 2014 Sep; 59(3):356-9. PubMed ID: 24762458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European pediatricians' approach to children with GER symptoms: survey of the implementation of 2009 NASPGHAN-ESPGHAN guidelines.
    Quitadamo P; Papadopoulou A; Wenzl T; Urbonas V; Kneepkens CM; Roman E; Orel R; Pavkov DJ; Dias JA; Vandenplas Y; Kostovski A; Miele E; Villani A; Staiano A
    J Pediatr Gastroenterol Nutr; 2014 Apr; 58(4):505-9. PubMed ID: 24663035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.
    Mearin F; Ponce J; Ponce M; Balboa A; Gónzalez MA; Zapardiel J
    Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):665-74. PubMed ID: 22330237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Symptom profile in gastroesophageal reflux disease in untreated patients and those with persistent symptoms despite treatment].
    Ponce J; Mearin F; Ponce M; Balboa A; Zapardiel J
    Gastroenterol Hepatol; 2010 Apr; 33(4):271-9. PubMed ID: 20133018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to short-term proton pump inhibitor treatment in laryngopharyngeal reflux patients.
    Siupsinskiene N; Adamonis K; Toohill RJ; Sereika R
    J Laryngol Otol; 2008 Nov; 122(11):1206-12. PubMed ID: 18331659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities.
    Patterson Burdsall D; Flores HC; Krueger J; Garretson S; Gorbien MJ; Iacch A; Dobbs V; Homa T
    J Am Med Dir Assoc; 2013 Jun; 14(6):429-32. PubMed ID: 23583000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of reflux disease in clinical praxis in hungary.
    Hritz I; Prónai L; Szalay F; Tulassay Z
    Z Gastroenterol; 2005 Jun; 43(6):575-80. PubMed ID: 15986286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastroesophageal reflux and proton pump inhibitors: panacea or prescription abuse?].
    Mouterde O; Bellaïche M; Dumant C; Mallet E
    Arch Pediatr; 2010 Jun; 17(6):739-40. PubMed ID: 20654868
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence on consumer behavior: the impact of direct-to-consumer advertising on medication requests for gastroesophageal reflux disease and social anxiety disorder.
    Khanfar NM; Polen HH; Clauson KA
    J Health Commun; 2009; 14(5):451-60. PubMed ID: 19657925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.